HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.47
Dividend & YieldN/A£ (N/A)
Beta 0.62
Market capitalization 1.25B
Operating cash flow -222.76M
ESG Scores unknown

Company description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.02M -2.37M 7.49M 20.64M
Total Cashflows From Investing Activities 43.75M 119.03M -125.44M -306.32M
Net Borrowings -4.63M -116k -579k -579k
Total Cash From Financing Activities -8.23M -1.49M 296.43M 650.03M
Change To Operating Activities 7.18M 22.96M 30.1M 63.46M
Issuance Of Stock 3.87M 251k 318.93M 717.32M
Net Income -74.81M -106.02M -125.73M -194.65M
Change In Cash 771k 35.12M 114.47M 141.91M
Effect Of Exchange Rate -1.9M -1.5M 5.55M 2.43M
Total Cash From Operating Activities -32.85M -80.91M -62.07M -204.22M
Depreciation 3.59M 4.94M 6.06M 7.19M
Change To Account Receivables -486k -271k -4.69M -35.63M
Other Cashflows From Financing Activities -2.02M -1.28M -9.6M -39.4M
Change To Netincome 31.13M 3.87M 28.29M -49.27M
Capital Expenditures -6.36M -8.56M -7.95M -16.4M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -67.32M -100.41M -110.69M -155.12M
Net Income -74.81M -106.02M -125.73M -194.65M
Selling General Administrative 48.65M 52.93M 61.35M 127.12M
Gross Profit -44M -93.45M -135.32M -201.19M
Ebit -92.64M -146.39M -196.67M -328.32M
Operating Income -92.64M -146.39M -196.67M -328.32M
Interest Expense -1.01M -1.03M -787k -592k
Income Tax Expense 3.96M 3.27M 4.83M 11.92M
Total Revenue 214.11M 204.89M 227.98M 356.13M
Cost Of Revenue 258.11M 298.34M 363.3M 557.32M
Total Other Income ExpenseNet 25.32M 45.98M 85.98M 173.19M
Net Income From Continuing Ops -71.29M -103.68M -115.52M -167.04M
Net Income Applicable To Common Shares -74.81M -106.02M -125.73M -194.65M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 119.86M 152.22M 205.17M 333.15M
Total Stockholder Equity 389M 288.01M 484.12M 986.89M
Other Current Liabilities 10.97M 12.02M 13.26M 56.49M
Total Assets 532.12M 465.12M 724.12M 1.37B
Common Stock 66.66M 66.69M 72.77M 86.45M
Other Current Assets 930k
Retained Earnings -183M -289.73M -415.59M -610.33M
Treasury Stock -243k -3.85M 4.48M 5.57M
Cash 86.04M 121.16M 235.63M 377.54M
Total Current Liabilities 85.48M 113.1M 158.4M 311.66M
Other Stockholder Equity -243k -3.85M 4.48M 5.57M
Property, Plant, and Equipment 16.62M 26.37M 32.19M 53.15M
Total Current Assets 370.54M 317.02M 530.74M 1.21B
Net Tangible Assets 385.46M 284.62M 480.58M 983.35M
Net Receivables 51.23M 77.35M 63.97M 147.73M
Accounts Payable 25.62M 23.96M 31.61M 41.18M


Insider Transactions

Here are the insider transactions of stock shares related to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Salata (Jean Eric)D2022-08-18819.67k
Salata (Jean Eric)D2022-01-27
Shih (Edith)D2022-01-27
Eldar (Dan)D2022-01-27
Hutchison Healthcare Holdings LtdD2022-01-27
JPMorgan Chase & CoD2022-01-27
M&G Alternatives Investment Management, Ltd.D2022-01-27
To (Simon)D2022-01-27
Canada Pension Plan Investment BoardD2022-01-27
Capital International IncD2022-01-27
Carlyle Asia Growth Partners III, L.P.D2022-01-27
Carter (Paul)D2022-01-27
General Atlantic Singapore Fund FII Pte LtdD2022-01-035.83M
Eldar (Dan)D2021-12-31
Hogg (Christian)D2021-12-31
Capital International IncD2021-12-31
Carter (Paul)D2021-12-31
Chig Fung (Johnny Cheng)D2021-12-31
Shih (Edith)D2021-12-31
Hutchison Healthcare Holdings LtdD2021-12-31
Su (Weiguo)D2021-12-31
To (Simon)D2021-12-31
Hutchison Healthcare Holdings LtdD2021-07-1615.6M
Hutchison Healthcare Holdings LtdD2021-06-3015.58M
Salata (Jean Eric)D2021-06-30
Canada Pension Plan Investment BoardD2021-06-30
Carlyle Asia Growth Partners III, L.P.D2021-06-30
Capital International IncD2020-12-31
Carter (Paul)D2020-12-31
Chig Fung (Johnny Cheng)D2020-12-31
Shih (Edith)D2020-12-31
Eldar (Dan)D2020-12-31
General Atlantic Singapore Fund FII Pte LtdD2020-12-31
Hogg (Christian)D2020-12-31
Hutchison Healthcare Holdings LtdD2020-12-31
To (Simon)D2020-12-31

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Here is the result of two systematic investment strategies applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the equity curve of the two systematic investment strategies applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 12.04% on the backtest period.

Performance at glance

Performance

12.04 %

Latent gain

395.0 £

Invested capital

3281.0 £

Annualized return

2.92 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

This is the result of two momentum investment strategies applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows all the entries opened by the momentum investment system on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 momentum entries
  • The first momentum investment strategy would give 10.96% of return on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10. That represents 907.75£ of latent gain with 8282.25£ of employed capital.
  • The second momentum investment strategy would give 10.53% of return on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10. That represents 700.5£ of latent gain with 6651.5£ of employed capital.
Performance at glance (1Q Momentum)

Performance

10.96 %

Latent gain

907.75 £

Invested capital

8282.25 £

Annualized return

6.84 %
Performance at glance (2Q Momentum)

Performance

10.53 %

Latent gain

700.5 £

Invested capital

6651.5 £

Annualized return

2.89 %

Momentum equity curve on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the equity curve of the two momentum strategies applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 momentum equity

Note: the dividends potentially given by HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the employed capital evolution of the two momentum strategies on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 since the beginning:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Buy the dip entry openings on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The performance achieved by the robo-advisor on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 is 14.5%. That represents 465.5$ of latent gain with 3210.5£ of employed capital. The following chart shows HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

14.5 %

Latent gain

465.5 £

Invested capital

3210.5 £

Annualized return

6.84 %

Equity curve of the strategy applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the result of the investment strategy applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Note: the dividends potentially given by HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the employed capital evolution since the beginning of the investment strategy on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

In this section, I will compare the three previous investment strategies applied to HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10.

Equity curve comparison on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 investment strategy comparison

Employed capital comparison on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 investment comparison

Performance comparison on HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 12.04% 395.0£ 3281.0£ 2.92%
Momentum 1 quarter 10.96% 907.75£ 8282.25£ 2.82%
Momentum 2 quarters 10.53% 700.5£ 6651.5£ 2.89%
Non-directional 14.5% 465.5£ 3210.5£ 6.84%
Annualized return comparison

Automatic investment

2.92 %

Momentum 1Q

2.89 %

Momentum 2Q

2.89 %

Non-directional

6.84 %

Correlated stocks

Here are the most positively and negatively correlated stocks with HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 and the other stocks. There may be false positives or some missing correlated stocks. If the price of HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10
Country Hong Kong
City Central
Address Cheung Kong Center
Phone 852 2128 1188
Website www.hutch-med.com
FullTime employees 2110
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XLON
Ticker HCM.XLON
Market www.londonstockexchange.com

HUTCHISON CHINA MEDITECH LIMITED ORD USD0.10 ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown